8 April 2019 - The Scottish Medicines Consortium (SMC) announced that Aimovig (erenumab) has been accepted for adults who have previously tried at least three prior preventive treatments that have failed. 

This means that eligible patients in Scotland will have access to the first treatment designed specifically to prevent migraine to be funded by the NHS. 

Chronic migraine is defined as more than 15 headache days per month of which more than eight involve migraine symptoms.

Read The Scotsman article